These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8402737)

  • 1. Drug resistance in rat colon cancer cell lines is associated with minor changes in susceptibility to cytotoxic cells.
    Van de Vrie W; Van der Heyden SA; Gheuens EE; Bijma AM; De Bruijn EA; Marquet RL; Van Oosterom AT; Eggermont AM
    Cancer Immunol Immunother; 1993 Oct; 37(5):337-42. PubMed ID: 8402737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development and purification of a bispecific antibody for lymphokine-activated killer cell targeting against the rat colon carcinoma CC531.
    Kuppen PJ; Eggermont AM; Smits KM; van Eendenburg JD; Lazeroms SP; van de Velde CJ; Fleuren GJ
    Cancer Immunol Immunother; 1993 Jun; 36(6):403-8. PubMed ID: 8500112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.
    Savas B; Cole SP; Tsuruo T; Pross HF
    J Clin Immunol; 1996 Nov; 16(6):348-57. PubMed ID: 8946280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
    Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
    Treichel RS; Olken S
    Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of correlation between mdr-1 expression and volume-activation of cloride-currents in rat colon cancer cells.
    De Greef C; van der Heyden S; Viana F; Eggermont J; De Bruijn EA; Raeymaekers L; Droogmans G; Nilius B
    Pflugers Arch; 1995 Jun; 430(2):296-8. PubMed ID: 7675640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity.
    Scheper RJ; Dalton WS; Grogan TM; Schlosser A; Bellamy WT; Taylor CW; Scuderi P; Spier C
    Int J Cancer; 1991 Jun; 48(4):562-7. PubMed ID: 1710609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma.
    Savas B; Kerr PE; Ustun H; Cole SP; Pross HF
    Anticancer Res; 1998; 18(6A):4355-61. PubMed ID: 9891492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug-resistant colonic cancer cell line LoVoDx is efficiently killed by lymphokine-activated killer cells from patients with carcinoma of the colon.
    Mooney EF; Dye JF; Guillou PJ; Monson JR
    Br J Surg; 1993 Oct; 80(10):1259-61. PubMed ID: 8242292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of NKR-P1 is not an absolute requirement for natural killer activity in BDIX rats.
    Pinard D; Olsson NO; Chambers WH; Martin F
    Cancer Immunol Immunother; 1996 Jan; 42(1):15-23. PubMed ID: 8625362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of rat colon carcinoma cells to lymphokine activated killer-mediated cytotoxicity is decreased by alpha1,2-fucosylation.
    Marionneau S; Bureau V; Goupille C; Hallouin F; Rocher J; Vaydie B; Le Pendu J
    Int J Cancer; 2000 Jun; 86(5):713-7. PubMed ID: 10797295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of function-associated molecules in target cell lysis: analysis of rat adherent lymphokine-activated killer cells.
    Jaso-Friedmann L; Leary JH; Evans DL
    Nat Immun; 1993; 12(6):316-25. PubMed ID: 8268715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Morphological observation on NK/LAK cell-mediated lysis of human oral carcinoma cells].
    Zheng YJ; Zhang J; Wang SM; Zhang JR
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Apr; 24(4):392-6. PubMed ID: 15090306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the relationship between stage of differentiation and NK/LAK susceptibility of colon carcinoma cells.
    Blottière HM; Zennadi R; Grégoire M; Aillet G; Denis MG; Meflah K; Le Pendu J
    Int J Cancer; 1993 Feb; 53(3):409-17. PubMed ID: 8428794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
    Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
    J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts.
    Dannemann BR; Morris VA; Araujo FG; Remington JS
    J Immunol; 1989 Oct; 143(8):2684-91. PubMed ID: 2477453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.
    Mizutani Y; Bonavida B; Nio Y; Yoshida O
    Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of a bi-specific anti-CD161A x anti-tumor antibody for rat NK cell targeting.
    Hagenaars M; Ensink NG; Jonges LE; Chambers WH; Eggermont AM; van de Velde CJ; Fleuren GJ; Kuppen PJ
    Immunobiology; 1999 Feb; 200(1):31-48. PubMed ID: 10084694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
    Hermann GG; Zeuthen J; Claësson MH
    Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.